Pyelonephritis Treatment Market to Reach USD 1,682.83 Million by 2033 | North America Holds 39.5% Market Share | Key Players: Pfizer Inc., Bayer AG, Merck & Co.

The global pyelonephritis treatment market was valued at USD 1,073.23 million in 2025 and is projected to reach USD 1,682.83 million by 2033, growing at a CAGR of 5.8% during the forecast period from 2026 to 2033. The market is witnessing steady growth driven by the rising prevalence of urinary tract infections (UTIs), increasing incidence of kidney infections among elderly and diabetic populations, and growing awareness regarding early diagnosis and treatment of renal complications. Pyelonephritis, a serious bacterial kidney infection commonly caused by ascending urinary tract infections, is becoming a major healthcare concern due to the increasing burden of antimicrobial resistance and recurrent infections worldwide. Factors such as poor hygiene conditions, rising hospitalization rates, increasing catheter-associated infections, and growing prevalence of chronic kidney disorders are further contributing to the expansion of the pyelonephritis treatment market globally. In addition, the increasing demand for effective antibiotic therapies, improved diagnostic technologies, and hospital-based infection management solutions is supporting market growth across both developed and emerging economies.

The market is also benefiting from continuous advancements in combination antibiotic therapies, rapid diagnostic testing methods, and research focused on reducing antimicrobial resistance. Pharmaceutical companies are increasingly investing in next-generation anti-infective drugs, broad-spectrum antibiotics, and precision medicine approaches to improve treatment outcomes and reduce recurrence rates. Rising healthcare expenditure, growing adoption of telemedicine for infection management, and expanding access to healthcare services are creating strong growth opportunities for the market. However, challenges such as antibiotic resistance, side effects associated with prolonged antibiotic usage, and the high treatment costs for severe or chronic pyelonephritis cases may limit market expansion. Leading companies, including Pfizer Inc., GlaxoSmithKline plc, Merck & Co., Inc., Cipla Limited, and Teva Pharmaceutical Industries Ltd., are actively focusing on advanced antibiotic development, strategic collaborations, and expanded clinical research programs to strengthen their market presence. Recent investments in antimicrobial resistance research, novel infection management therapies, and improved renal care solutions are expected to support the long-term development of the global pyelonephritis treatment market during the forecast period.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://www.datamintelligence.com/download-sample/pyelonephritis-treatment-market?sai-v

Key Developments

February 2026: Rising prevalence of urinary tract infections, increasing antimicrobial resistance, and growing awareness regarding kidney infection management accelerated growth in the global pyelonephritis treatment market. Companies including Pfizer, Merck & Co., and GlaxoSmithKline expanded research activities and antibiotic treatment portfolios for complicated urinary tract infections and pyelonephritis therapies worldwide.

January 2026: Increasing adoption of advanced diagnostic technologies, rapid microbial testing, and targeted antibiotic therapies strengthened market expansion across North America and Europe. Healthcare providers increasingly focused on early diagnosis and personalized antimicrobial treatment strategies to reduce hospitalization rates and severe kidney infection complications.

December 2025: Growing incidence of recurrent urinary tract infections, diabetes-related kidney complications, and catheter-associated infections accelerated demand for pyelonephritis treatment solutions globally. Pharmaceutical companies focused on next-generation antibiotics, combination therapies, and resistance management strategies to improve patient outcomes.

November 2025: Expansion of hospital infection control programs, improved access to healthcare services, and increasing awareness regarding antimicrobial stewardship supported strong adoption of pyelonephritis treatment therapies worldwide. Countries including the United States, Germany, China, and Japan witnessed rising utilization of broad-spectrum and targeted antibiotic treatments in hospital and outpatient settings.

October 2025: Rising advancements in molecular diagnostics, AI-assisted infection detection, and microbiome research improved treatment capabilities in the pyelonephritis treatment market globally. Research organizations focused on rapid pathogen identification, resistance profiling technologies, and novel anti-infective therapeutic development for severe urinary tract infections.

September 2025: Increasing collaborations between pharmaceutical companies, healthcare institutions, and infectious disease research organizations accelerated innovation in pyelonephritis treatment solutions worldwide. Companies expanded clinical trials evaluating novel antibiotics, beta-lactam combinations, and antimicrobial resistance prevention strategies for kidney infection management.

August 2025: Growing emphasis on preventive healthcare, infection surveillance, and antibiotic resistance mitigation strengthened expansion of the pyelonephritis treatment market across Asia-Pacific and Europe. Healthcare systems increasingly adopted evidence-based infection management protocols and rapid screening technologies to reduce complications associated with kidney infections.

July 2025: Rising investments in infectious disease therapeutics, hospital care infrastructure, and precision medicine accelerated progress in pyelonephritis treatment globally. Companies including AbbVie and Bayer expanded anti-infective research and strategic partnerships focused on advanced urinary tract infection therapies.

June 2025: Increasing focus on antimicrobial stewardship, early infection diagnosis, and chronic kidney health supported strong adoption in the global pyelonephritis treatment market. North America remained the leading region due to advanced healthcare infrastructure and high treatment accessibility, while Asia-Pacific emerged as the fastest growing market driven by rising healthcare expenditure, increasing infection awareness, and expanding hospital care facilities.

Key Players
Pfizer Inc. | Teva Pharmaceuticals USA, Inc. | Bayer AG | Sandoz AG | Bristol-Myers Squibb Company | Viatris Inc. | Melinta Therapeutics, LLC. | Cipla | Merck & Co., Inc. | Sun Pharmaceutical Industries Ltd. | Others

Key Highlights
Pfizer Inc. - Holds a 16.1% share, driven by broad-spectrum antibiotic portfolios, extensive infectious disease research capabilities, and strong global pharmaceutical distribution networks.

Teva Pharmaceuticals USA, Inc. - Holds a 12.4% share, supported by cost-effective generic antibiotic manufacturing, large-scale pharmaceutical production infrastructure, and strong hospital supply capabilities.

Bayer AG - Holds a 10.3% share, strengthened by advanced anti-infective treatment portfolios, strong healthcare innovation expertise, and expanding urology therapeutic applications.

Sandoz AG - Holds a 9.8% share, fueled by extensive generic anti-infective medicine offerings, integrated global supply chains, and strong regulatory compliance expertise.

Bristol-Myers Squibb Company - Holds a 8.1% share, driven by innovative pharmaceutical research initiatives, advanced infectious disease therapeutic programs, and strong clinical development capabilities.

Viatris Inc. - Holds a 7.6% share, supported by diversified generic medicine portfolios, broad global healthcare access strategies, and strong antibiotic commercialization capabilities.

Melinta Therapeutics, LLC. - Holds a 6.2% share, powered by specialized antibiotic drug development expertise, antimicrobial resistance treatment innovation, and advanced infectious disease research programs.

Cipla - Holds a 8.9% share, strengthened by affordable generic antibiotic production, expanding global pharmaceutical exports, and strong emerging market healthcare presence.

Merck & Co., Inc. - Holds a 7.4% share, driven by anti-infective drug development capabilities, advanced clinical research infrastructure, and diversified pharmaceutical treatment portfolios.

Sun Pharmaceutical Industries Ltd. - Holds a 5.8% share, supported by large-scale generic medicine manufacturing operations, broad hospital distribution channels, and integrated pharmaceutical development expertise.

Others - Hold a combined 7.4% share, comprising regional anti-infective drug manufacturers, specialty antibiotic therapy developers, generic pharmaceutical companies, and emerging antimicrobial research firms expanding advanced pyelonephritis treatment applications globally.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=pyelonephritis-treatment-market?sai-v

Market Drivers

Increasing prevalence of urinary tract infections, kidney infections, and antimicrobial-resistant bacterial infections is significantly driving growth of the pyelonephritis treatment market worldwide.

Growing adoption of advanced antibiotics, combination therapies, and rapid diagnostic solutions for kidney infection management is accelerating market expansion globally.

Rising investments in infectious disease research, antimicrobial drug development, and hospital care infrastructure are strengthening demand for pyelonephritis treatment solutions across healthcare systems.

Increasing focus on early diagnosis, effective infection management, and prevention of renal complications is contributing to rapid commercialization of advanced pyelonephritis therapeutics.

Continuous advancements in molecular diagnostics, antimicrobial susceptibility testing, targeted antibiotic therapies, and precision medicine approaches are improving treatment effectiveness and patient outcomes.

Expansion of healthcare infrastructure, emergency care facilities, telemedicine services, and diagnostic laboratory networks is improving adoption of pyelonephritis treatment solutions worldwide.

Growing investments from pharmaceutical companies, biotechnology firms, healthcare organizations, and governments in antibiotic research and infection control programs are accelerating market growth.

Rising demand for outpatient infection management, broad-spectrum antibiotics, and personalized antimicrobial therapies is further propelling global pyelonephritis treatment market expansion.

Industry Developments

Rapid advancement in next-generation antibiotics and AI-powered infectious disease diagnostic systems improving pathogen identification and treatment precision for pyelonephritis management.

Increasing adoption of rapid molecular testing, automated microbiology platforms, and digital healthcare technologies supporting faster diagnosis and optimized antibiotic stewardship programs.

Growing investments in antimicrobial resistance research, novel antibacterial therapies, and hospital infection control initiatives accelerating innovation in pyelonephritis treatment solutions.

Expansion of specialty infectious disease clinics and advanced diagnostic laboratories improving accessibility and commercialization of kidney infection management services.

Rising collaborations among pharmaceutical companies, healthcare providers, diagnostic firms, and research institutes driving development of integrated infectious disease treatment ecosystems.

Strategic product launches and commercialization of broad-spectrum antibiotics, combination antimicrobial therapies, and advanced urinary tract infection diagnostics supporting global market expansion.

Continuous innovation in remote patient monitoring technologies, telehealth-based infection management systems, and precision antimicrobial treatment platforms improving clinical outcomes and patient care efficiency.

Regional Insights

North America 39.5% share: "Leads the market due to advanced healthcare infrastructure, strong antibiotic development capabilities, increasing prevalence of urinary tract infections, and high investments in infectious disease diagnostics and treatment technologies."

Europe 28.7% share: "Growth supported by strong healthcare reimbursement systems, increasing focus on antimicrobial stewardship, expanding adoption of advanced diagnostics, and rising investments in infectious disease management programs."

Asia Pacific 24.0% share: "Fastest-growing region driven by expanding healthcare infrastructure, rising prevalence of urinary tract infections, increasing healthcare access, and growing pharmaceutical investments across China, India, Japan, South Korea, and Southeast Asia."

Latin America 3.7% share: "Emerging growth supported by improving healthcare services, increasing awareness regarding kidney infection management, and rising adoption of advanced antibiotic therapies."

Middle East & Africa 4.1% share: "Gradual growth driven by expanding healthcare modernization initiatives, increasing infectious disease burden, and rising investments in diagnostic and antimicrobial treatment infrastructure."

Speak to our analyst and get customization in the report as per your requirements: https://www.datamintelligence.com/customize/pyelonephritis-treatment-market?sai-v

Key Segments
➥ By Type

Acute Pyelonephritis: Represents the dominant segment, driven by increasing incidence of bacterial kidney infections, rising hospitalization rates, and growing demand for prompt antibiotic treatment.

Chronic Pyelonephritis: Represents a significant segment, supported by increasing prevalence of recurrent urinary tract infections and long-term kidney complications requiring extended treatment management.

Complicated Pyelonephritis: Represents a rapidly growing segment, fueled by rising cases associated with diabetes, urinary tract obstructions, catheter-associated infections, and antimicrobial resistance concerns.

Others: Represents a moderate segment, driven by expanding diagnosis of atypical and secondary kidney infection conditions across vulnerable patient populations.

➥ By Treatment Type

Antibiotic Therapy: Represents the dominant segment, driven by widespread use of broad-spectrum and targeted antibiotics as the primary treatment approach for bacterial kidney infections.

Supportive Care Therapy: Represents a significant segment, supported by increasing utilization of hydration therapy, pain management, and fever control during infection treatment.

Hospitalization and Surgical Interventions: Represents a rapidly growing segment, fueled by rising cases of severe and complicated pyelonephritis requiring inpatient care, drainage procedures, and surgical management.

Others: Represents a moderate segment, driven by expanding adoption of combination therapies, preventive management strategies, and emerging antimicrobial treatment approaches.

➥ By Route of Administration

Oral: Represents the dominant segment, driven by increasing prescription of oral antibiotics for mild to moderate pyelonephritis cases and outpatient treatment convenience.

Intravenous: Represents a rapidly growing segment, supported by rising hospitalization of severe infection cases and increasing use of IV antibiotics for rapid therapeutic response.

Others: Represents a moderate segment, fueled by expanding utilization of alternative administration methods and supportive therapeutic delivery approaches.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription
Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.